Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.
LOXO-IDH-20001
Phase 1 other active
Quick answer
Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations. for Advanced Hematologic Malignancies is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Advanced Hematologic Malignancies
- Phase
- Phase 1
- Modality
- other
- Status
- active